The Journal of Phytopharmacology, 2021;10(5):298-315 DOI:10.31254/phyto.2021.10505

Research Article

Safety Assessment of TGT Primaage using Wistar Rats through Oral Gavage Administration

Kunjan Shah¹ , Sudhakar Jadhav¹ , Manish Patel¹ , Jaydip Mistry¹ , Akashrao Shinde¹ , Liliya Mito² , Kanchan Khare¹

Kunjan Shah,Sudhakar Jadhav,Manish Patel,Jaydip Mistry,Akashrao Shinde,Liliya Mito,Kanchan Khare

1. Department of Toxicology, Jai Research Foundation, Vapi, Gujarat, India
2. The Mitomasa SDN BHD, Selangor D.E., Malaysia

*Author to whom correspondence should be addressed.

Received: 16th July, 2021 / Accepted: 9th August, 2021

Abstract

TGT Primaage is one of the astonishing extracts, obtained from a combination of Moringa oleifera and Centella asiatica. At present, there is no finding reported regardin g the repeated exposure of this extract. This study investigates the No Observed Adverse Effect Level (NOAEL) and effects of repeated-dose administration of Astragalin and Isoquercetin (components of interest) present in TGT Primaage on Wistar rats. Rats were divided into 3 treatment and a control group (10 rats/sex/group). To assess reversibility, persistence, or delayed effect, additional control and high dose groups were treated similarly and observed further without any treatment. TGT Primaage was administered orally, through gavage for 90 days, at 0, 250, 500, and 1000 mg/kg body weight/day. No mortality, morbidity, and clinical sign of toxicity was observed. Abnormality related to neurological and functional parameters was not seen. No change in body weight and food consumption was observed. Treatment did not lead to any adverse effect in clinical pathology parameters and organ weights. TGT Primaage did not alter morphological and histopathological characteristics of organs. From these results, it is evident that TGT Primaage appears to be safe and devoid of any toxicity. The No Observed Adverse Effect Level (NOAEL) of TGT Primaage for both sexes were found to be 1000 mg/kg body weight/day.